尋常性乾癬の成人患者におけるSAR441566の有効性と安全性を評価する研究

基本情報

NCT ID

NCT06073119

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

221

治験依頼者名

Sanofi

概要

This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details included a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits was 7.

対象疾患

介入

依頼者（Sponsor）